<?xml version="1.0" encoding="UTF-8"?>
<p>On the other hand, the use of camrelizumab is associated with a good safety profile; the high incidence of all adverse drug reactions is related to reactive capillary hemangiomas, which are generally unthreatening and self-limited [
 <xref rid="B81-pharmaceuticals-13-00096" ref-type="bibr">81</xref>]. Currently, camrelizumab is being investigated for its effectiveness in COVID-19 (NCT04268537).
</p>
